AUTL
Autolus Therapeutics Ltd
NASDAQ: AUTL · HEALTHCARE · BIOTECHNOLOGY
$1.41
+0.00% today
Updated 2026-04-30
Market cap
$383.25M
P/E ratio
—
P/S ratio
355.35x
EPS (TTM)
$-1.08
Dividend yield
—
52W range
$1 – $3
Volume
1.7M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
8.0
Growth
A5.0
Quality
C+2.5
Profitability
F6.7
Valuation
B—/9
Piotroski F-Score
—
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$8.81
+524.82%
12-Month target
—
—
Intrinsic (DCF)
$3.39
Margin of safety
+57.82%
1 Strong Buy10 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 83,655.00% QoQ
+ 57.82% below intrinsic value
Risks
- Thin margins at 0.00%
- Negative free cash flow $-91.09M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $6.19M | $1.70M | $10.12M | $75.56M | $1.08M |
| Net income | $-148.84M | $-208.38M | $-220.66M | $-287.53M | $-90.20M |
| EPS | — | — | — | — | $-1.08 |
| Free cash flow | $-123.15M | $-156.57M | $-241.09M | $-302.66M | $-91.09M |
| Profit margin | -2,402.95% | -12,272.26% | -2,180.45% | -380.51% | — |
Peer comparison
Smart narrative
Autolus Therapeutics Ltd trades at $1.41. Our Smart Value Score of 35/100 indicates the stock is weak. TTM revenue stands at $1.08M. Our DCF model estimates intrinsic value at $3.39.
Frequently asked questions
What is Autolus Therapeutics Ltd's stock price?
Autolus Therapeutics Ltd (AUTL) trades at $1.41.
Is Autolus Therapeutics Ltd overvalued?
Smart Value Score 35/100 (Grade D, Sell). DCF value $3.39.
What is the price target of Autolus Therapeutics Ltd (AUTL)?
The analyst target price is $8.81, representing +524.8% upside from the current price of $1.41.
What is the intrinsic value of Autolus Therapeutics Ltd (AUTL)?
Based on our DCF model, intrinsic value is $3.39, a +57.8% margin of safety versus $1.41.
What is Autolus Therapeutics Ltd's revenue?
TTM revenue is $1.08M.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio355.35x
ROE-29.60%
Beta2.00
50D MA$1.51
200D MA$1.64
Shares out0.27B
Float0.03B
Short ratio—
Avg volume1.7M
Performance
1 week-8.86%
1 month+19.01%
3 months+3.60%
YTD-27.64%
1 year—
3 years—
5 years—